Related Experiment Video
Updated: Oct 6, 2025
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Prognostic immunologic signatures in epithelial ovarian cancer
Nicole E James1,2, Morgan Woodman1, Jennifer R Ribeiro3,4
1Women and Infants Hospital, Department of Obstetrics and Gynecology, Program in Women's Oncology, Providence, RI, USA.
Abstract:
Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.
Insights
Epithelial ovarian cancer (EOC) shows promise for immune-based prognostic signatures. Research is advancing to identify genomic profiles that predict patient outcomes, improving treatment strategies for this deadly gynecologic malignancy.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Epithelial ovarian cancer (EOC) frequently recurs after chemotherapy.
- Immunotherapy, including PD-1 inhibitors, is a focus in EOC treatment.
- Current immunotherapy response rates in EOC are low, but tumors show immunogenicity.
Purpose of the Study:
- To review advances in immune-based prognostic signatures for EOC.
- To highlight genomic profiles as potential prognostic markers.
- To identify future research directions in EOC immunotherapy.
Main Methods:
- Literature review of recent studies on EOC immunotherapy and genomics.
- Analysis of immune-related genomic profiles in EOC.
- Discussion of clinical trial data and prognostic marker development.
Main Results:
- Evidence suggests ovarian tumors are immunogenic.
- Immune-related genomic profiles may serve as prognostic markers in EOC.
- Development of immune-based prognostic signatures is advancing.
Conclusions:
- Immune-based prognostic signatures hold potential for predicting EOC patient outcomes.
- Further research is needed to refine these signatures and improve immunotherapy efficacy.
- Genomic profiling offers a promising avenue for personalized EOC treatment strategies.
